Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Rigosertib Plus Pembrolizumab in Treating Patients with Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Melanoma
Melanoma
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic), and that has not responded to previous treatment with PD-1 or PD-L1 inhibitors (refractory). Rigosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may change the immune system to make immunotherapy more effective. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rigosertib in combination with pembrolizumab may be more effective in treating patients with unresectable metastatic melanoma that has not responded to previous treatment with PD-1 or PD-L1 inhibitors than giving either drug alone.
Melanoma
II
Johnson, Douglas
NCT05764395
VICCMEL2218
Aveir DR i2i Study - Aveir Dual-Chamber Leadless i2i IDE Study
Not Available
II
Richardson, Travis
CRE-ARR0013
CONFORM Pivotal - An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion
Not Available
II
Ellis, Christopher
CRE-ARR0011
Sphere- Treatment of Persistent Atrial Fibrillation with the Sphere -9- mapping and ablation cathether and the AFFERA Mapping and Ablation system
Not Available
II
Richardson, Travis
CRE-ARR0015
Developing a Trustworthy Multilevel Intervention to Improve Equity in Lung Cancer Screening
Lung
Lung
Lung
N/A
Richmond, Jennifer
VICC-VDTHO23221
LESS VT- Flexibility Sensor Enabled Substrate Targeted Ablation for teh Reduction of VT (LESS VT) Study
Not Available
II
Tandri, Harikrishna
CRE-ARR0016
VANISH 2- Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2
Not Available
III
Kanagasundram, Arvindh
CRE-CHF0001